Glaxo smith kline, Pharmaceutical company

Sanofi and GlaxoSmithKline (GSK) said on Monday they had begun a phase 2 trial of their COVID-19 vaccine candidates, and if results are positive, a phase 3 study could start in the second quarter of 2021.According to CNN, the "protein subunit" vaccine uses Sanofi's recombinant antigen technology with a GlaxoSmithKline adjuvant, an immune booster. The phase 2 study will include 720 volunteers aged 18 and older in the United States, Honduras and Panama.The trial will assess the dosage of the compes' vaccine; three different antigen doses will be tested with a fixed adjuvant dose and the two injections will be given 21 days apart.CNN further reported that phase 1/2 trials showed the vaccine candidate elicited an immune response in younger adults that's comparable to patients who recovered from COVID-19, but the vaccine did not produce the desired immune response in older adults.The second phase of the trial will include equal numbers of adults aged from 18 to 59 years, and 60 years and above."Over the past few weeks, our teams have worked to refine the antigen formulation of our recombinant-protein vaccine, based on learnings from our initial Phase 1/2 study," Thomas Triomphe, executive vice president and head of Sanofi Pasteur, said in a statement quoted by CNN."We are confident that our vaccine candidate has strong potential and we are very encouraged by the latest preclinical data," Triomphe added.The compes said that the vaccine could be available in the fourth quarter if trial results are positive and the vaccine is authorised.In statements, the compes also said Sanofi has begun work against new coronavirus variants "which will be used to inform next stages of the Sanofi/GSK development program."( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Glaxo Smith KlineFOLLOW

Glaxo smith kline, Latest News

New Delhi, Dec 11 The Central Consumer Protection Authority (CCPA) has imposed a penalty of Rs 10 lakh ... ...

Sydney, March 15 A new combination drug therapy against a type of malaria in kids aged 2 to ... ...

London, Dec 3 British drugmaker GlaxoSmithKline has claimed that early laboratory tests show that its antibody drug against ... ...

Paris, Sep 29 French drugmaker Sanofi said it has dropped the development of its mRNA Covid-19 vaccine. The ... ...

Berlin, Aug 17 The second mRNA Covid-19 Vaccine developed by German biopharmaceutical company CureVac and its British partner ... ...

Mumbai, July 8 The Drugs Controller General of India (DGCI) has granted approval to Sanofi and Glaxo Smith ... ...

GlaxoSmithKline (GSK) Pharmaceuticals clocked 6 per cent growth in revenue for the January to March quarter at Rs 807 crore as compared to the same period of the previous fiscal. ...

Sanofi and GlaxoSmithKline (GSK) said on Monday they had begun a phase 2 trial of their COVID-19 vaccine candidates, and if results are positive, a phase 3 study could start in the second quarter of 2021. ...